16th Mar 2016 09:12
LONDON (Alliance News) - Rex Bionics PLC on Wednesday reiterated its sales guidance for its financial year ending this month and remains confident on its prospects.
The company, which is behind the Rex Robot technology, designed to help the mobility of wheelchair users, said sales in its second half to the end of March will be higher than in its first.
Rex said the medium-term outlook for robotic mobility aids remains very attractive and said feedback from initial demonstrations of its technology in the US has confirmed the potential interest shown by customers.
Rex will focus its short-term energies on the US market in order to capitalise on this opportunity and will continue to support its registration process for the Chinese market.
"Most people who see a robotic exoskeleton immediately grasp its value and its potential to transform lives. We have delivered commercial sales, clinical evidence and new partnerships, and are especially pleased with the agreement we announced last week with the US Army. Our goal is to be the market leader in this exciting new technology," said Crispin Simon, Rex Bionics' chief executive.
Shares in Rex were untraded on Wednesday, having last traded at 40.50 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
RXB.L